AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 7 Sep - Radhika Biyani appointed Additional Independent Director from 5 Sept 2026; board committees reconstituted.
Source: Bse
Alpa Laboratories Limited (ALPA)
Small CapPharma stocks · Small cap · NSE
Alpa Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 08:29 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -6.5% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ALPAD candles · FIT view-23.7%Latest close ₹52.25 on 2026-10-19
Bar
+2.4%
RSI
26
MACD hist
-0.41
52W pos
13%
2026-10-19O ₹51.01H ₹54.28L ₹51.01C ₹52.25Vol 5,277 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ALPANifty PharmaNifty 500
- ALPA
- -23.8%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -18.2 pp
Chart stats
19 Oct 2026- From 52W high
- -44.3%
- 52W range position
- 13%
- ATR (14)
- 5.6%
- Volume vs 20D
- 0.23x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹50.6 - ₹62.4
₹93.9
₹46.1 - ₹93.9
₹2.9
Latest completed session
20-session average
30.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST32
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +25.2% · PAT -91.7% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model+40.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence66
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -92% YoY · margin compression · Rev +25% YoY
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹23.9 Cr | +25.2% | -23.8% |
| EBITDA | ₹-4 Cr | -1020.9% | -210.0% |
| Operating margin | -16.6% | -1880 bps | -2801 bps |
| PAT | ₹1 Cr | -91.7% | -29.0% |
| PAT margin | 4.1% | -5749 bps | -29 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 30.60
- P/B
- 0.67
- EV/EBITDA
- 127.00
- Market Cap
- 124.00Cr
Profitability
- ROE
- 8.38%
- ROCE
- 9.40%
- ROA
- 1.65%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 2.00%
- EPS 5Y
- 24.00%
- Revenue 3Y
- 4.00%
- EPS 3Y
- 6.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- —
- Altman Z
- 3.00
- Book Value
- 88.50
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 6/5
- OCF
- 9.00 Cr
- EPS TTM
- 1.94
Shareholding
- Promoter Hold
- 57.19%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 24%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 23.9-23.8% vs prev
Net Profit
₹ CrLatest: 1.0-29.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 26.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~7.0% over last month) — short-term momentum negative.
- RSI(14) at 26 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 44% off 52W high · 13% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
11
RS percentile
Stage 4 Downtrend
1M return
-12.0%
3M return
-23.8%
6M return
-23.8%
1Y return
-41.5%
RS 1D
-2
RS 20D
-11
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 19.5% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.1%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 59.54-1.24%
RS vs Nifty 50060
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation16/30
Growth7/25
Quality0/20
Balance Sheet10/15
Cash Flow4/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
32
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
32/100 · legacy band WATCHLIST
Positive drivers
- Fair-value margin of safety is positive at 40.2%.
- Balance sheet contributes 10/15 to the score.
- Valuation contributes 16/30 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 7/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
30.6
PB
0.7
EV/EBITDA
127.0
ROE
8.4%
ROCE
9.4%
FCF Yield
—
Debt/Equity
0.0
MoS
+40.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
32
Previous: 32
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+40.2%
Previous: +40.2%
Score history
12 stored score snapshots. Latest stored move: +2 points.
20 Oct 2026
v4.3-runtime-valuation
30
30
30
30
30
30
30
30
30
30
30
32
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹62.15
+15.9% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹87.3
+40.2% MoS
PEG
1.82
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BALAXI
Small
BALAXI PHARMACEUTICALS LIMITED
Pharmaceuticals
match 166
9
51.7
0.6%
-5589%
OVERVALUED
JHS
Small
JHS Svendgaard Laboratories Limited
Pharmaceuticals
match 164
12
—
-1.2%
—
OVERVALUED
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 164
23
23.6
7.9%
-44%
OVERVALUED
BROOKS
Small
Brooks Laboratories Limited
Pharmaceuticals
match 163
60
12.1
22.0%
+68%
UNDERVALUED
CURIS
SME
Curis Lifesciences Ltd.
Pharmaceuticals
match 159
33
30.0
—
+57%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Alpa Laboratories Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
66Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 36th percentile within Pharma. Main check: results consistency is weak at 29/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
3 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
49th percentile
overall median 67 · Pharma: 36th pctile, median 70 · Small: 54th pctile, median 66
Evidence depth
Financial-only
3 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 57.2%.
- ▸Promoter pledge is zero.
- ▸6 years of positive FCF.
- ▸Debt/equity is 0.02.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE trend is -3.9%.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸OPM spread across recent quarters is 29.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Alpa Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Cessation 22 Jul - Ms. Jyoti Jain ceased as Independent Director on 21 July 2026 after completing tenure.
Source: Bse
Announcement
Clarification 9 Apr - Alpa Laboratories clarifies no undisclosed price-sensitive event or near-term announcement exists.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.